avizakimab   Click here for help

GtoPdb Ligand ID: 12270

Synonyms: BOS 161721 | BOS161721
Compound class: Antibody
Comment: Avizakimab (BOS161721; Boston Pharmaceuticals) is a humanized anti-IL-21 antibody that inhibits IL-21 bioactivity. It was developed for potential to treat systemic lupus erythematosus (SLE), an auotimmune condition in which IL-21 is implicated as a driving factor [3-5]. IL-21 has been explored as a therapeutic target in a range of autoimmune disease models (SLE, rheumatoid arthritis, type 1 diabetes and psoriasis). Peptide sequences for avizakimab are claimed in Boston Pharmaceuticals' patent US10022443B2 [1].
No information available.
Summary of Clinical Use Click here for help
Avizakimab (BOS161721) has been advanced as a clinical lead.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03371251 Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care Phase 1/Phase 2 Interventional Boston Pharmaceuticals
NCT03036865 Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects Phase 1 Interventional Boston Pharmaceuticals Safety, tolerability, target engagement and pharmacological activity were demonstrated in this Phase 1 study. 2